TIAA Trust National Association Makes New $207,000 Investment in Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT)

TIAA Trust National Association bought a new position in Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 101,834 shares of the company’s stock, valued at approximately $207,000. TIAA Trust National Association owned approximately 4.53% of Lixte Biotechnology at the end of the most recent reporting period.

Separately, Atlas Legacy Advisors LLC purchased a new stake in Lixte Biotechnology in the 4th quarter valued at about $26,000. Institutional investors and hedge funds own 5.10% of the company’s stock.

Lixte Biotechnology Stock Up 1.6 %

Lixte Biotechnology stock opened at $1.27 on Friday. The stock has a market cap of $2.86 million, a P/E ratio of -0.73 and a beta of 0.19. The company’s 50 day moving average price is $1.70 and its two-hundred day moving average price is $1.86. Lixte Biotechnology Holdings, Inc. has a 52 week low of $1.02 and a 52 week high of $3.87.

Lixte Biotechnology (NASDAQ:LIXT) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.27) EPS for the quarter.

About Lixte Biotechnology

LIXTE Biotechnology Holdings, Inc, a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer.